<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05003531</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI112A201</org_study_id>
    <nct_id>NCT05003531</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis</brief_title>
  <official_title>A Phase II Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Trial to Evaluate the Efficacy and Safety of IBI112 in Different Dose Regimens for the Treatment of Subjects With Moderate-to-severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of IBI112 administered in&#xD;
      different dose regimens for the treatment of patients with plaque psoriasis&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 23, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients achieving Psoriasis Area and severity index(PASI) 90 at week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>PASI 90 is defined as at least a 90% reduction in PASI relative to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving Psoriasis Area and severity index(PASI) 75 at week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>PASI 75 is defined as at least a 75% reduction in PASI relative to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving Psoriasis Area and severity index(PASI) 100 at week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>PASI 100 is defined as at least a 100% reduction in PASI relative to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with Physician Global Assessment(PGA) Score of Cleared(0) or Minimal(1) at week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>PGA of psoriasis is used to determine the participant's psoriasis lesions overall at a given time point.PGA score ranges from 0-4,0=cleared, 1= minimal ,2=mild, 3= moderate, 4= marked, 5= severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with Physician Global Assessment(PGA) Score of Cleared(0) at week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>PGA of psoriasis is used to determine the participant's psoriasis lesions overall at a given time point.PGA score ranges from 0-4,0=cleared, 1= minimal ,2=mild, 3= moderate, 4= marked, 5= severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Dermatology life quality index(DLQI) at week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>The DLQI is a 10-item questionnaire that measures the impact of skin disease on participant's quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving Psoriasis Area and severity index(PASI) 90 at week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>PASI 90 is defined as at least a 90% reduction in PASI relative to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving Psoriasis Area and severity index(PASI) 100 at week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>PASI 100 is defined as at least a 100% reduction in PASI relative to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving Psoriasis Area and severity index(PASI) 75 at week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>PASI 75 is defined as at least a 75% reduction in PASI relative to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with Physician Global Assessment(PGA) Score of Cleared(0) or Minimal(1) at week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>PGA of psoriasis is used to determine the participant's psoriasis lesions overall at a given time point.PGA score ranges from 0-4,0=cleared, 1= minimal ,2=mild, 3= moderate, 4= marked, 5= severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with Physician Global Assessment(PGA) Score of Cleared(0) at week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>PGA of psoriasis is used to determine the participant's psoriasis lesions overall at a given time point.PGA score ranges from 0-4,0=cleared, 1= minimal ,2=mild, 3= moderate, 4= marked, 5= severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Dermatology life quality index(DLQI) at week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>The DLQI is a 10-item questionnaire that measures the impact of skin disease on participant's quality of life</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>IBI112 dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive IBI112 dose 1 subcutaneous injection(SC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IBI112 dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive IBI112 dose 4 subcutaneous injection(SC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IBI112 dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive IBI112 dose 2 subcutaneous injection(SC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IBI112 dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive IBI112 dose 3 subcutaneous injection(SC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo subcutaneous injection(SC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI112 dose 2</intervention_name>
    <description>Participants will receive placebo or dose 2 IBI112 SC</description>
    <arm_group_label>IBI112 dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI112 dose 4</intervention_name>
    <description>Participants will receive placebo or dose 4 IBI112 SC</description>
    <arm_group_label>IBI112 dose 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI112 dose 1</intervention_name>
    <description>Participants will receive placebo or dose 1 IBI112 SC</description>
    <arm_group_label>IBI112 dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI112 dose 3</intervention_name>
    <description>Participants will receive placebo or dose 3 IBI112 SC</description>
    <arm_group_label>IBI112 dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Participants will receive placebo SC</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Diagnosis of plaque-type psoriasis with or without psoriatic arthritis for at least 6&#xD;
             months prior to first administration of any study agent&#xD;
&#xD;
          -  Must be a candidate for phototherapy or systemic treatment for psoriasis (either new&#xD;
             to treatment or having had previous treatment) Exclusion criteria&#xD;
&#xD;
          -  History of or current signs or symptoms of severe, progressive, or uncontrolled renal,&#xD;
             hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic,&#xD;
             cerebral, or psychiatric disease&#xD;
&#xD;
          -  Participant has history of erythrodermic psoriasis, generalized or localized pustular&#xD;
             psoriasis, medication-induced or medication-exacerbated psoriasis, or new onset&#xD;
             guttate psoriasis&#xD;
&#xD;
          -  Has received any therapeutic agent directly targeted to IL-12, IL-17, or IL-23within 6&#xD;
             months of the first administration of study agent&#xD;
&#xD;
          -  Has received any therapeutic agent directly targeted toTNF-a within 3 months of the&#xD;
             first administration of study agent&#xD;
&#xD;
          -  Has received any conventional therapeutic agent within 1 months of the first&#xD;
             administration of study agent&#xD;
&#xD;
          -  Has received any topic therapeutic agent within 2 weeks of the first administration of&#xD;
             study agent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianzhong zhang</last_name>
    <phone>+86 010 88326666</phone>
    <email>rmzjz@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>PeKing University People's Hostpital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianzhong Zhang</last_name>
      <phone>+86 010 88326666</phone>
      <email>rmzjz@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 5, 2021</study_first_submitted>
  <study_first_submitted_qc>August 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2021</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

